1. Home
  2. Press Releases
  3. BioFactura Announces Entry into Non-Exclusive License Agreement with Momenta Pharmaceuticals

BioFactura Announces Entry into Non-Exclusive License Agreement with Momenta Pharmaceuticals

BioFactura, Inc., an emerging Maryland biopharmaceutical research and manufacturing company, announced today entry into a non-exclusive license agreement with Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, relating to one of the biosimilar product candidates that Momenta is developing.  As part of this non-exclusive license agreement, BioFactura is developing a cell line using its NS0-based StableFastTM Biomanufacturing Platform, a proprietary system to rapidly generate stable cell lines that have the potential to lower cost, produce follow-on biologics and are single-use technology compatible.  The companies are actively working together to further optimize productivity.  Momenta has the right to obtain an exclusive research and commercial license to StableFastTM for clinical development and commercial manufacture of the undisclosed biosimilar product candidate.

BioFactura’s Chief Executive Officer and President, Darryl Sampey, said, “This agreement has the potential to benefit patients worldwide.  We believe that this commitment by a proven leader in our industry is an endorsement of the value our StableFastTM Biomanufacturing Platform brings.  We look forward to continuing to work with Momenta and the expansion of BioFactura’s efforts in biosimilars development.”

BioFactura’s Chairman of the Board and Chief Medical Officer, Dr. Jeffrey Hausfeld, said, “BioFactura believes that the establishment of this agreement between BioFactura and Momenta attests to the value of BioFactura’s proprietary technology in this space. Our organization is pleased to support the scientific and business development teams at Momenta.”

September 21, 2016 Press Releases
About BioFactura

BioFactura (Frederick MD) develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.